Maia Biotechnology Receives FDA Orphan Drug Designation For THIO For The Treatment Of Small-Cell Lung Cancer
Maia Biotechnology Receives FDA Orphan Drug Designation For THIO For The Treatment Of Small-Cell Lung Cancer
$MAIA Biotechnology(MAIA.US)$ ("MAIA", the "Company"), a targeted therapy, immuno-oncology company focused on developing potential first-in-class oncology drugs, announced today that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to THIO, a telomere-targeting agent currently in development to evaluate its activity in multiple cancer indications, for the treatment of small-cell lung cancer (SCLC).
This is the second orphan drug designation granted to THIO, following receipt of orphan designation for hepatocellular carcinoma (HCC).
$MAIA Biotechnology(MAIA.US)$ ("MAIA", the "Company"), a targeted therapy, immuno-oncology company focused on developing potential first-in-class oncology drugs, announced today that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to THIO, a telomere-targeting agent currently in development to evaluate its activity in multiple cancer indications, for the treatment of small-cell lung cancer (SCLC).
$Maia Biotech(MAIA.US)$專注於開發潛在的一流腫瘤學藥物的靶向治療、免疫腫瘤學公司Maia今天宣佈，美國食品和藥物管理局(FDA)已授予正在開發中的端粒靶向製劑thio治療小細胞肺癌(SCLC)的孤兒藥物名稱(ODD)，以評估其在多種癌症適應症中的活性。
This is the second orphan drug designation granted to THIO, following receipt of orphan designation for hepatocellular carcinoma (HCC).
這是繼收到肝細胞癌孤兒稱號後，授予THIO的第二個孤兒藥物稱號。
譯文內容由第三人軟體翻譯。
風險及免責聲明
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能，分享給你的好友吧